Icecure Medical Ltd (ICCM) Q1 2025 Earnings Call Highlights: Strategic Advances and Market ...
Release Date: May 28, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Icecure Medical Ltd (NASDAQ:ICCM) has submitted a postmarket study plan to the FDA, which is a significant milestone towards obtaining marketing authorization for their cryoablation technology.
The company experienced growth in sales in North America and Europe, with an 11% increase in North America and a 60% increase in Europe year-over-year.
Icecure Medical Ltd (NASDAQ:ICCM) has strong support from its largest shareholder, who provided a $2 million unsecured loan, demonstrating confidence in the company's technology and business plan.
The company is optimistic about potential FDA marketing authorization, which would allow them to commence commercial sales and access reimbursement under the CPT code.
There is a high level of interest from breast surgeons and interventional radiologists in participating in the planned post-market study, indicating strong market interest in the technology.
Revenue for the first quarter of 2025 was $725,000, a slight decrease from $743,000 in the same period in 2024.
Gross profit and gross margin both declined, with gross profit at $218,000 compared to $269,000 the previous year, and gross margin dropping from 36% to 30%.
Sales in Asia declined significantly, with a 60% decrease in Japan and a 40% decrease in other parts of Asia.
The company reported a net loss of $3.59 million for the quarter, slightly less than the $3.61 million loss in the previous year.
The FDA has not provided a specific timeline for the review of the postmarket study plan, creating uncertainty around the timing of potential marketing authorization.
Warning! GuruFocus has detected 4 Warning Signs with ICCM.
Q: Is the postmarket study still expected to involve a minimum of 400 patients over 25 sites, and when might the FDA respond to the submission? A: Yes, the postmarket study will require 400 patients across at least 25 sites. The FDA's top management will continue to review it, but no specific timeline for their response can be guaranteed. The package submitted was extensive, and ongoing discussions with the FDA are expected. - CEO
Q: How long is the postmarket study expected to take once approved? A: The recruitment for the postmarket study is expected to be completed within three years, with 400 patients recruited during this period. - CEO
Q: Can you provide more details on the potential for expanded reimbursement? A: With more records and claims on our specific CPT code for breast cancer, we believe we can increase reimbursement. After FDA marketing authorization, we plan to apply to the AMA to move from CPT 3 to CPT 1, which includes efficiency. Preparations for this process are underway. - CEO
Q: What is the market opportunity for the ProSense system in Japan? A: Japan has over 100,000 new breast cancer cases annually, with nearly two-thirds being low-risk, early-stage cases. The market opportunity is significant, and we expect fewer limitations compared to the US market. - CEO
Q: Can you provide a geographic breakdown of revenue growth this quarter? A: In North America, revenue increased by about 11% year-over-year, and in Europe, it increased by about 60%. In Asia, there was a decline, with Japan seeing a 60% decrease, but these numbers fluctuate due to the small base. - CFO
Q: Are there any new tariffs affecting the ProSense system in the US market? A: Yes, there were initial tariffs imposed by the US administration, but there is currently a freeze on these taxes. We will need to see future decisions by the administration. - CFO
Q: Will you expand your sales team following postmarket study approval? A: Yes, we plan to increase our sales team after receiving marketing authorization. We have a professional Vice President for North America, and we will build a team including sales reps, regional managers, and clinical application specialists. - CEO
Q: What are your commercial strategies regarding pricing and sales? A: We anticipate a 60-40 split between placements and console sales. For placements, we require a commitment to a monthly number of probes over 2-3 years at a higher price. We will also sell consoles and single-use probes separately. - CEO
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
Peloton looks to place equipment in gyms, launch marketplace, TechCrunch says
Peloton (PTON) CEO Peter Stern said the company is exploring ways to expand its customer base by making its products available for use in gyms and launching a peer-to-peer marketplace for equipment, Ivan Mehta of TechCrunch reports, citing comments made by Stern at the Bloomberg Tech Summit. Peloton plans to distribute its machines to commercial gyms via is subsidiary Precor and will add Peloton workouts to compatible Precor equipment. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders' Hot Stocks on TipRanks >> Read More on PTON: Disclaimer & DisclosureReport an Issue Peloton's Strategic Initiatives and Margin Improvements Justify Buy Rating Peloton Interactive call volume above normal and directionally bullish Peloton's 'Repowered' Marketplace: A Strategic Move to Boost Revenue and Brand Loyalty Repowered: Peloton Stock (NASDAQ:PTON) Ticks Up with New Used Market Peloton price target lowered to $8.50 from $10 at Citi Sign in to access your portfolio
Yahoo
30 minutes ago
- Yahoo
Broadcom Sinks as CEO Becomes Defensive on AI Opportunity -- Should Investors Buy the Dip?
Broadcom shares fell despite another strong quarter of AI revenue growth. However, its CEO got defensive when asked about the AI market opportunity he touted only six months ago. Still, the company is only at the beginning of its custom AI chip opportunity. 10 stocks we like better than Broadcom › Broadcom (NASDAQ: AVGO) once again reported robust artificial intelligence (AI) revenue growth in its fiscal second-quarter results released this week, with promises that the strong revenue growth would continue. The stock slipped despite an upbeat outlook, although it remains up more than 75% over the past year. Let's take a closer look at Broadcom's most recent results and the AI opportunity in front of it to see whether investors should buy this small dip. Broadcom CEO Hock Tan initially got investors excited back in December 2024 when he talked about the company having a $60 billion to $90 billion serviceable addressable market (SAM) opportunity in fiscal year 2027 with its three largest hyperscale (meaning they operate huge data centers) customers. However, when asked whether its SAM had increased, Tan told analysts he's "not playing the SAM game" and to "stop talking about SAM now." It was an unusual and defensive response from an executive who, only six months ago, was hyping Broadcom's SAM opportunity. However, Tan had said earlier that he anticipates Broadcom's current AI semiconductor revenue growth to sustain into fiscal 2026 after projecting it would grow by 60% to $5.1 billion in fiscal Q3. As one analyst on the call pointed out, that would imply $30 billion or more in AI semiconductor revenue in fiscal 2026. Much of Broadcom's AI semiconductor revenue growth is currently coming from its networking portfolio, particularly Ethernet switches. The company said its AI networking revenue surged by 170% year over year and represented 40% of its AI revenue. Perhaps, the bigger opportunity, though, is in custom AI chips. The company stated that custom AI chip revenue rose by double digits in the quarter and that it expects demand in the back half of 2026 to accelerate as inference demand surges. This is most likely coming from Alphabet, which was Broadcom's first customer for custom AI chips. However, the company said it still expects its three largest custom chip customers to each deploy 1 million AI chip clusters in 2027, mostly for training foundational AI models. Turning to Broadcom's results, its overall revenue climbed 20% year over year to $15 billion in the quarter, while adjusted earnings per share (EPS) soared 44% to $1.58 (adjusting for its prior 10-for-1 stock split). The results edged past analyst expectations for adjusted EPS of $1.56 on revenue of $14.99 billion, as compiled by LSEG. Adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA), meanwhile, surged 67% year over year to $10 billion. AI-related revenue jumped 46% year over year to $4.4 billion. Total semiconductor solutions revenue rose 17% year over year to $8.4 billion, as the recovery in its non-AI chip revenue continues to be slow. Infrastructure software revenue, meanwhile, increased by 25% to $6.6 billion. The company credited the growth to strong sales of its VMware Cloud Foundation (VCF) platform and the transition of customers to subscription models. Its VCF platform helps customers create hybrid and multicloud environments, giving them the flexibility to manage workloads across both public clouds and their own on-premise data centers. Approximately 87% of VMware's top 10,000 customers have now adopted its VCF platform. Broadcom continues to generate strong cash flow, with cash flow from operations coming in at nearly $6.6 billion and free cash flow of $6.4 billion. It ended the quarter with nearly $9.5 billion in cash and equivalents and $67.3 billion in debt after buying back $4.2 billion worth of shares in the quarter. Its debt is a result of its $69 billion acquisition of VMware in 2023. Looking ahead, Broadcom forecasts fiscal Q3 revenue to increase by 21% to $15.8 billion, with semiconductor revenue rising 25% to $9.1 billion and infrastructure software revenue increasing 16% to $6.7 billion. It expects adjusted EBITDA to be about 66% of revenue, or about $10.4 billion. Broadcom continues to see strong AI revenue growth, led by its networking portfolio. But the best opportunity may still be in front of the company, with its custom AI chips. Only Alphabet is truly ramped up, and it has a huge opportunity with other customers. Now, Tan's sudden reluctance to talk about Broadcom's AI semiconductor SAM is disappointing, and the extent to which China's ByteDance -- one of its suspected in-progress large AI chip customers -- and the new Chinese export controls might have on that is unknown. Still, he did not back down from the growth of the company's three large hyperscale customers or that they plan to each deploy 1 million AI chip clusters in 2027. He also still has Apple as well as other customers that aren't quite as far along, which should also power growth in later years. From a valuation perspective, Broadcom now trades at a forward price-to-earnings (P/E) ratio of about 31.5, based on fiscal 2026 analyst estimates, and a price/earnings-to-growth ratio (PEG) of less than 0.4. Stocks with PEG ratios below 1 are generally considered undervalued. Given the growth opportunities still in front of it, I think investors can use this price dip to start building positions. The biggest risk would be a slowdown in spending on AI infrastructure, but we still appear to be in the early innings. Before you buy stock in Broadcom, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Broadcom wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor's total average return is 792% — a market-crushing outperformance compared to 171% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Geoffrey Seiler has positions in Alphabet. The Motley Fool has positions in and recommends Alphabet and Apple. The Motley Fool recommends Broadcom. The Motley Fool has a disclosure policy. Broadcom Sinks as CEO Becomes Defensive on AI Opportunity -- Should Investors Buy the Dip? was originally published by The Motley Fool
Yahoo
39 minutes ago
- Yahoo
Is this the Tesla stock buying opportunity I've been waiting for?
Down by 22% in little over a week, Tesla (NASDAQ:TSLA) sometimes seems to be behaving more like a penny share than a company worth almost $900bn that last year had a revenue close to $100bn. Still, I have been eyeing Tesla stock as a possible addition to my portfolio for a while already – so could this latest crash offer me the sort of buying opportunity I have been hoping for? My answer depends on the price, something I will get into below. First, though, I ought to explain why I like the idea of owning some Tesla stock at all. The company is barely more than two decades old. But it has already built up a massive global manufacturing and sales footprint for its electric vehicles. Sales volumes declined slightly last year (and that decline has accelerated this year), but remain substantial. I think Tesla's recent history points to two important factors. First, it is a serious contender in the electric vehicle space. That is a competitive area and Tesla risks rivals like BYD leaving it behind, but it has strengths such as proprietary technology, a vertically integrated business model and unique designs. A second point also jumps out at me from Tesla's development. It has demonstrated expertise not only in imagining new products, but in bringing them to market at scale and quickly. It is doing the same now with its power storage division, which, unlike the car business, had a very strong first quarter. Such expertise could help Tesla capitalize on some of the other ideas that sit somewhere between its drawing board and widespread real world use, from automated taxi fleets to robotics. That matters because, seen purely as a car company, Tesla stock would look wildly overvalued to me. As far as I am concerned, the only possible justification for the current valuation, let alone a higher one, is the potential of the company's plans beyond the electric car business. That, however, is where I start to have serious concerns about valuation, even after the recent crash in Tesla stock. While the power storage business is growing quickly, even taken together with the car business I do not think the joint valuation ought to be anywhere close to $900bn. Meanwhile, the other ideas are highly speculative for now – it remains to be seen when they are commercialized at scale, if they ever are. So I think it is hard to justify anything more than a fairly modest valuation for them at this point, no matter how large the long-term potential may seem to be. Taken as the sum of the parts, I do not think Tesla is worth anything like its market capitalization. So, although the share is cheaper than a couple of weeks back, it is still far too expensive for me to consider buying yet. The post Is this the Tesla stock buying opportunity I've been waiting for? appeared first on The Motley Fool UK. More reading 5 Stocks For Trying To Build Wealth After 50 One Top Growth Stock from the Motley Fool C Ruane has no position in any of the shares mentioned. The Motley Fool UK has recommended Tesla. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. Motley Fool UK 2025 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
